Multimorbidity, Polypharmacy, and COVID-19

infection within the UK Biobank cohort.

Ross McQueenie<sup>1</sup>, Hamish M.E. Foster<sup>1</sup>, Bhautesh D. Jani<sup>1</sup>, Srinivasa Vittal Katikireddi <sup>1</sup>,

Naveed Sattar<sup>2</sup>, Jill P. Pell<sup>1</sup>, Frederick K. Ho<sup>1</sup>, Claire L. Niedzwiedz<sup>1</sup>, Claire E. Hastie<sup>1</sup>, Jana

Anderson<sup>1</sup>, Patrick B. Mark<sup>2</sup>, Michael Sullivan<sup>2</sup>, Catherine A. O'Donnell<sup>1</sup>, Frances S. Mair<sup>1\*</sup>,

Barbara I. Nicholl<sup>1\*</sup>

1. Institute of Health and Wellbeing, College of Medical, Veterinary and Life

Sciences, University of Glasgow, Glasgow, UK

2. British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of

Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK

^ Joint first author

\* Joint senior author

**Corresponding author:** 

Dr. Barbara I. Nicholl

General Practice and Primary Care, University of Glasgow

1 Horselethill Road, Glasgow, G12 9LX, UK

Email:barbara.nicholl@glasgow.ac.uk

Tel: 0141 330 8327

**ABSTRACT** 

BACKGROUND: It is now well recognised that the risk of severe COVID-19 increases with some long-term conditions (LTCs). However, prior research primarily focuses on individual LTCs and there is a lack of data on the influence of multimorbidity (≥2 LTCs) on the risk of COVID-19. Given the high prevalence of multimorbidity, more detailed understanding of the associations with multimorbidity and COVID-19 would improve risk stratification and help protect those most vulnerable to severe COVID-19. Here we examine the relationships between multimorbidity, polypharmacy (a proxy of multimorbidity), and COVID-19; and how these differ by sociodemographic, lifestyle, and physiological prognostic factors.

METHODS AND FINDINGS: We studied data from UK Biobank (428,199 participants; aged 37-73; recruited 2006-2010) on self-reported LTCs, medications, sociodemographic, lifestyle, and physiological measures which were linked to COVID-19 test data. Poisson regression models examined risk of COVID-19 by multimorbidity/polypharmacy and effect modification COVID-19 prognostic factors (age/sex/ethnicity/socioeconomic status/smoking/physical activity/BMI/systolic blood pressure/renal function). 4,498 (1.05%) participants were tested; 1,324 (0.31%) tested positive for COVID-19. Compared with no LTCs, relative risk (RR) of COVID-19 in those with 1 LTC was no higher (RR 1.12 (CI 0.96-1.30)), whereas those with ≥2 LTCs had 48% higher risk; RR 1.48 (1.28-1.71). Compared with no cardiometabolic LTCs, having 1 and ≥2 cardiometabolic LTCs had a higher risk of COVID-19; RR 1.28 (1.12-1.46) and 1.77 (1.46-2.15), respectively. Polypharmacy was associated with a dose response increased risk of COVID-19. All prognostic factors were associated with a higher risk of COVID-19 infection in multimorbidity; being non-white, most socioeconomically deprived, BMI ≥40 kg/m2, and reduced renal function were associated

with the highest risk of COVID-19 infection: RR 2.81 (2.09-3.78); 2.79 (2.00-3.90); 2.66 (1.88-

3.76); 2.13 (1.46-3.12), respectively. No multiplicative interaction between multimorbidity

and prognostic factors was identified. Important limitations include the low proportion of

UK Biobank participants with COVID-19 test data (1.05%) and UK Biobank participants being

more affluent, healthier and less ethnically diverse than the general population.

CONCLUSIONS: Increasing multimorbidity, especially cardiometabolic multimorbidity, and

polypharmacy are associated with a higher risk of developing COVID-19. Those with

multimorbidity and additional factors, such as non-white ethnicity, are at heightened risk of

COVID-19.

**Author summary** 

Why was this study done?

Multimorbidity is a growing global challenge, but thus far LTC prognostic factors for

severe COVID-19 primarily involve single conditions and there is a lack of data on the

influence of multimorbidity on the risk of COVID-19.

As countries move from the lockdown phase of COVID-19, clinicians need more

3

information about risk stratification to appropriately advise patients with

multimorbidity about risk prevention steps.

What did the researchers do and find?

Participants with multimorbidity (≥2 LTCs) had a 48% higher risk of a positive COVID-

19 test, those with cardiometabolic multimorbidity had a 77% higher

risk, than those without that type of multimorbidity.

Those from non-white ethnicities with multimorbidity had nearly three times the risk

of having COVID-19 infection compared to those of white ethnicity

People with multimorbidity with the highest risk of COVID-19 infection were the

deprived, those with BMI ≥40 kg/m<sup>2</sup>, and those most socioeconomically

reduced renal function.

What do these findings mean?

Individuals with ≥2 LTCs, especially if these are cardiometabolic in nature, should be

particularly stringent in adhering to preventive measures, such as physical distancing

and hand hygiene.

Our findings have implications for clinicians, occupational health and employers

when considering work-place environments, appropriate advice for patients, and

adaptations that might be required to protect such staff, identified here, as higher

4

risk.

Introduction

COVID-19 is an ongoing pandemic caused by the severe acute respiratory syndrome

coronavirus 2 (SARS-CoV-2).(1-3) COVID-19 clinical manifestations range from asymptomatic

and mild upper respiratory symptoms to severe respiratory failure and death.(4) A range of

prognostic factors for greater mortality from COVID-19 have been identified including

age,(5) male sex,(6) non-white ethnicity,(7) obesity,(8) pre-existing long-term conditions

(LTCs; e.g. hypertension,(9) diabetes(10), chronic kidney disease(11)), and multimorbidity

(presence of >2 LTCs).(11-13) As a result, a key mitigation strategy in many countries is the

identification and protection of those deemed vulnerable or at higher risk of adverse

outcomes.(14)

For example, in both the UK and the USA, age (≥70 in UK and ≥65 in USA), severe obesity

(BMI ≥40 kg/m²), being immunocompromised, and certain LTCs (e.g.

cardiac/respiratory/renal disease) are used to identify those at higher risk of severe

disease.(14, 15) Individuals who meet any of these criteria have been asked to be more

cautious and adhere to public health guidance (e.g. social distancing) more strictly than the

general population. In the UK, this higher-risk group is distinct from those with specific LTCs

(e.g. leukaemia) who are considered 'extremely high risk' and, as a result, are asked to

'shield' and not leave their homes at all.(16)

To date, LTC prognostic factors for severe COVID-19 primarily involve single conditions and

there is a lack of data on the influence of multimorbidity on the risk of COVID-19.(5, 13, 17)

Multimorbidity prevalence is increasing worldwide and is associated with higher mortality,

with different disease clusters associated with even higher mortality. (18-21) Polypharmacy,

closely linked to multimorbidity, (22) is also associated with adverse health outcomes. (23)

Therefore, it is plausible that the number of LTCs, type of LTCs, and polypharmacy are

associated with a higher risk of developing severe COVID-19. Furthermore, it is plausible

that the adverse consequences of multimorbidity on COVID-19 risk may be greater for

population subgroups (e.g. people aged  $\geq 65$  years, or those with a BMI  $\geq 40 \text{kg/m}^2$ ). Such

knowledge would benefit clinicians, as this is routinely collected information in many clinical

settings. Using a large UK population cohort, UK Biobank, we aimed to investigate:

1) the association between multimorbidity (by number and type of LTC, and by level of

polypharmacy) and COVID-19.

2) the potential effect modification of known COVID-19 sociodemographic and

physiological risk factors on the association between multimorbidity and COVID-19.

**Methods** 

Study design and data collection

Data came from UK Biobank, a longitudinal population-based cohort of 502,503 participants

aged between 37-73 years old at baseline from England, Wales and Scotland. (24) Baseline

data were collected across 22 assessment centres between 2006-2010. UK Biobank contains

detailed biological measurements and self-reported demographic, lifestyle, and health

information elicited by touch-screen questionnaire and nurse-led interview. COVID-19 test

samples were collected and processed between 16 March 2020 and 18<sup>th</sup> May 2020. COVID-

19 test results were provided by Public Health England (PHE).(25) Data presented here are

from participants recruited from 16 assessment centres located in England only (5

participants with COVID-19 test data were excluded as they attended baseline assessment

centres in Scotland or Wales). Participants who had died prior to the last available mortality

register extraction (14 February 2018) were also excluded. This resulted in a final eligible

study population of 428,199 participants.

This study was conducted as part of UK Biobank project number 14151 and is covered by

the generic ethics approval for UK Biobank studies from the NHS National Research Ethics

Service (16/NW/0274).

Outcomes

Our outcome of interest was confirmed COVID-19 infection (defined as at least one positive

test result). Whether or not participants received a COVID-19 test was used as an outcome

for a secondary analysis, presented in Supplementary Material (Tables S1-S3).

Measurement of LTCs

Physician-diagnosed LTCs were self-reported and confirmed at nurse-led interview at

baseline. Number of LTCs, based on 43 commonly occurring LTCs from previous UK Biobank

work,(21) were categorised into 0, 1, and ≥2. When used as a predictor variable for COVID-

19, LTCs were modelled using three measures: total number of LTCs; number of

cardiometabolic LTCs (diabetes, coronary heart disease, atrial fibrillation, chronic heart

failure, chronic kidney disease, hypertension, stroke/transient ischaemic attack, or

peripheral vascular disease); and number of respiratory LTCs (asthma, chronic obstructive

7

pulmonary disease, chronic bronchitis, emphysema, or bronchiectasis).

Measurement of polypharmacy

Participant medication numbers were based on self-report at baseline and categorised into:

0, 1-3, 4-6, 7-9 and, ≥10 medications.

Exposures

Sex was collected as a binary variable (male/female). Age at time of COVID-19 test was

calculated using age at baseline, and dates of baseline assessment and COVID-19 test

extract, and categorised as 48-59, 60-69, and 70-86 years. Ethnicity was self-reported and

categorised as Asian/Asian British, black/black British, Chinese, mixed, white and other.

Socioeconomic deprivation was measured using the Townsend score of participants'

postcode of residence derived from Census data on car ownership, household occupancy,

unemployment, and occupation and categorised into quintiles.(26) Smoking status was

dichotomised as never and current/former. Frequency of alcohol intake was categorised

into: "Never or special occasions only", "1-3 times a month", "1-4 times a week", or "Daily

or almost daily". Level of physical activity was defined as "none", "low", "medium", or

"high" using Metabolic Equivalent Task (MET) scores based on the International Physical

Activity Questionnaire (IPAQ) scoring protocol. (27) Assessment centre location, a categorical

variable, describes attendance at one of sixteen assessment centres included in this study.

BMI was derived from weight and height and categorised as <18.5, 18.5-25, 25-30, 30-35, or

>35 kg/m<sup>2</sup>. The UK Biobank study protocol is described in more detailed online.(28)

To assess potential effect modification on the association between multimorbidity and

COVID-19, known COVID-19 risk factors were re-categorised into dichotomous variables

based on at-risk status: age ( $</\ge65$  years), ethnicity (white/non-white), physical activity ( $</\ge$ 

current UK guidelines of 150 min/week moderate or 75 min/week vigorous physical activity), (29) and BMI ( $</\ge40$ kg/m²; severely obese). (15) Due to previously identified associations with severe COVID-19, two additional physiological risk factors were also included in this analysis: raised systolic blood pressure ( $</\ge140$  mmHg) as a marker of hypertension; (9) and reduced estimated glomerular filtration rate (eGFR;  $</\ge60$  ml/min/1.73 $^\circ$ m²), with <60 ml/min/1.73 $^\circ$ m² used as a marker of chronic kidney disease. (30) eGFR was calculated by the CKD-EPI equation. (31)

Statistical analyses

We compared participants who tested positive for COVID-19 with those who tested negative or were not tested, based on sociodemographics (age, sex, Townsend score and ethnicity), lifestyle (smoking status, frequency of alcohol intake, physical activity), BMI, LTCs, and medication counts using  $\chi^2$  tests. Poisson regression models were then used to test for an association between outcome measure (confirmed COVID-19 infection vs. no COVID-19 infection, including those with a negative result and those not tested) and number of LTCs (all, cardiometabolic and respiratory LTCs)/level of polypharmacy. We chose Poisson regression models rather than logistic regression to provide more interpretable relative risks as opposed to odds ratios.(32) Participants with no LTCs, no cardiometabolic LTCs, no respiratory LTCs, or not taking any medication formed the respective reference groups. Two models were conducted, adjusting for 1) sociodemographic variables (as above plus assessment centre location), and 2) as for model 1 adjustments plus lifestyle variables and BMI. For both  $\chi^2$  tests and Poisson regression models, p<0.01 was considered statistically significant.

Next, we assessed whether there was evidence of effect modification on an additive scale by examining how the association between multimorbidity and COVID-19 differed across strata of known COVID-19 risk factors: sex, age, ethnicity, Townsend score, smoking, physical activity, BMI, systolic blood pressure, and eGFR. For each risk factor, the reference category was participants in the lowest risk category for that risk factor who also had no LTCs. We used Poisson regression models to examine the association between LTC and COVID-19 across the other combinations of LTC and risk factor categories. We tested formally for interactions by performing ANOVA tests between two models for each risk factor: one model containing an interaction term between the risk factor and number of LTCs, and one without the interaction term. Interactions were considered significant if p<0.01 for each ANOVA. As a secondary analysis we re-ran the analyses with the outcome as tested vs. not tested for COVID-19. The number of participants in each model varied depending on the proportion missing data for any included variable, however, the maximum proportion of missing data for any variable of interest was 2.9% (N=12,350) for systolic blood pressure. All analyses were conducted using R studio v.1.2.1335 operating R v.3.6.1.

**Results** 

Demographic and lifestyle factors

Of 428,199 eligible participants, 1,324 (0.31%) tested positive for COVID-19. Participants who tested positive for COVID-19 were older and more likely to be male, non-white, in the most deprived quintile, current/former smokers, drink alcohol rarely, to have a BMI of ≥40 kg/m², do no physical activity, to have more LTCs (including cardiometabolic and respiratory LTCs), and to be taking more medications, compared to those who did not have a positive COVID-19 test (Table 1).

Table 1 – Cohort characteristics by COVID-19 test positive or not.

	COVID-19 test negative or not tested (n=426,875)	COVID-19 test positive (n=1,324)
Sex		
Female	234,507	628
Temale	54.9 %	47.4 %
Male	192,368	696
Wide	45.1 %	52.6 %
Age at COVID-19 test (years)		
48-59	94,652	381
46-39	22.2 %	28.8 %
60-69	139,817	307
60-69	32.8 %	23.2 %
70.00	192,406	636
70-86	45.1 %	48.0 %
Ethnicity		
White	399,388	1,139
wille	94.1 %	86.7 %
Asian or Asian	9,186	60
British	2.2 %	4.6 %
Black or black	7,650	76
British	1.8 %	5.8 %
	1,396	6
Cninese	0.3 %	0.5 %
	2,652	9
Mixed	0.6 %	0.7 %
	4,181	23
sian or Asian ritish lack or black ritish hinese lixed	1.0 %	1.8 %
Townsend quintile		
1 (lacat dansii (ad)	84,840	179
1 (least deprived)	19.9 %	13.5 %
2	86,510	207
2	20.3 %	15.6 %
2	85,788	222
3	20.1 %	16.8 %
4	85,402	290
4	20.0 %	21.9 %
-/	83,835	425
5 (most deprived)	19.7 %	32.1 %

Smoking status		
	235,056	642
Never	55.4 %	49 %
6 . 6 .	189,299	669
Current or Previous	44.6 %	51.0 %
Frequency of alcohol intake	1	
Never or special	82,785	363
occasions only	19.5 %	27.5 %
One to three times a	47,535	183
month	11.2 %	13.9 %
One to four times a	208,046	563
week	48.9 %	42.7 %
Daily or almost	87,211	209
daily	20.5 %	15.9 %
Physical activity level		
none	25,887	157
none	6.2 %	12.2 %
low	15,687	51
10 W	3.7 %	4.0 %
modium	335,775	957
medium	79.8 %	74.5 %
high	43,383	120
eek aily or almost aily  nysical activity level  one  w  edium  gh  VII (kg/m²)  .8.5  3.5-25	10.3 %	9.3 %
BMI (kg/m²)		
<18.5	2,138	7
10.3	0.5 %	0.5 %
18 5-25	135,563	297
10.5-25	31.9 %	22.7 %
25-30	182,243	551
23 30	42.9 %	42.1 %
30-35	75,201	282
30-33	17.7 %	21.5 %
≥35	29,210	172
	6.9 %	13.1 %
Number of long-term conditions		
0	148,826	351
U	35.0 %	26.8 %
1	139,963	385
_	32.9 %	29.4 %
≥ 2	136,508	572
<del></del>	32.1 %	43.7 %

Number of cardiometabolic lo	ng-term conditions	
	300,363	773
0	70.4 %	58.4 %
1	103,185	394
1	24.2 %	29.8 %
. 2	23,327	157
≥ 2	5.5 %	11.9 %
Number of respiratory long-te	rm conditions	
0	373,026	1,120
O	87.4 %	84.6 %
1	51,226	186
1	12.0 %	14.0 %
≥ 2	2,623	18
	0.6 %	1.4 %
Number of medications		
0	121,288	296
0	28.5 %	22.4 %
1-3	197,296	526
1-3	46.3 %	39.8 %
4-6	76,265	298
4-6	17.9 %	22.5 %
7 0	22,779	130
7-9	5.3 %	9.8 %
> 10	8,538	72
≥ 10	2 %	5.4 %

Table 1 footnote - This table uses participants with COVID-19 positive tests as positive group and all other participants as negative group. All chi squared tests p<0.01.

### Multimorbidity and COVID-19

In the fully adjusted model (Model 2), compared to those with no LTCs, participants with 1 LTC had no higher risk of having a positive test for COVID-19 (RR 1.12 (0.96-1.30) p=0.15), but those with  $\geq$ 2 LTCs had a 48% higher risk (RR 1.48 (1.28-1.71) p<0.01) (Table 2). Compared to those with no cardiometabolic LTCs, those with 1 cardiometabolic LTC had a 28% higher risk (RR 1.28 (1.12-1.46) p<0.01), and those with  $\geq$ 2 cardiometabolic LTCs had a 77% higher risk (RR 1.77 (1.46-2.15) p<0.01) (Table 2). Participants with one respiratory LTC

had no greater risk of a positive COVID-19 test compared to those with no respiratory LTCs (RR 1.14 (0.97-1.33) p=0.12; Table 2). There was a higher risk of having a positive COVID-19 test in those with  $\geq 2$  respiratory LTCs (RR 1.78 (1.10-2.88) p=0.02) compared to 0 respiratory LTCs but this did not meet our p-value threshold of 0.01. However, it is a similar higher risk observed (78%) as for participants with  $\geq 2$  cardiometabolic conditions (77%); the lack of statistical significance may be explained by the much lower number of participants in the group with  $\geq 2$  respiratory LTCs (N=2,641) compared to  $\geq 2$  cardiometabolic conditions (N=23,484).

Table 2 – Relative risk of positive COVID-19 test by LTC groups (Poisson regression).

Measure of Multimorbidity (n)	Model 1 RR (95% CI)	P value	Model 2 RR (95% CI)	P value			
Total number of LTCs	(55% 5.1)		(55% 6.1)				
0 (149,177)	1 (ref)	-	1 (ref)	-			
1 (140,348)	1.18 (1.02-1.36)	0.03	1.12 (0.96-1.30)	0.15			
≥2 (137,080)	1.73 (1.51-1.99)	***	1.48 (1.28-1.71)	***			
Number of cardiometabo	olic LTCs						
0 (301,136)	1 (ref)	-	1 (ref)	-			
1 (103,579)	1.41 (1.24-1.60)	***	1.28 (1.12-1.46)	***			
≥2 (23,484)	2.17 (1.82-2.60)	***	1.77 (1.46-2.15)	***			
Number of respiratory L	ΓCs						
0 (374,146)	1 (ref)	-	1 (ref)	-			
1 (51,412)	1.20 (1.03-1.41)	0.02	1.14 (0.97-1.33)	0.12			
≥2 (2,641)	2.09 (1.31-3.33)	***	1.78 (1.10-2.88)	0.02			
Number of medications	Number of medications						
0 (121,584)	1 (ref)	-	1 (ref)	-			
1 – 3 (192,822)	1.13 (0.98-1.31)	0.10	1.07 (0.93-1.24)	0.36			
4 – 6 (76,563)	1.58 (1.34-1.87)	***	1.41 (1.18-1.67)	***			
7 – 9 (22,909)	2.24 (1.81-2.77)	***	1.86 (1.49-2.33)	***			
≥ 10 (8,610)	3.09 (2.37-4.03)	***	2.42 (1.82-3.21)	***			

Table 2 footnote - Model 1: Adjusted for age, sex, Townsend score, ethnicity, and assessment centre location. Model 2: As model 1 and additionally adjusted for smoking status, alcohol intake frequency, BMI, and physical activity. RR = Relative risk; CI =

confidence interval; n = number of participants; LTC = long-term condition; Cardiometabolic LTC = diabetes, coronary heart disease, atrial fibrillation, chronic heart failure, chronic kidney disease, hypertension, stroke/TIA or peripheral vascular disease; Respiratory LTC = asthma, chronic obstructive pulmonary disease, chronic bronchitis, emphysema, or bronchiectasis. \*\*\*p<0.01 Note: These results show the RR of a positive COVID-19 test versus a negative COVID-19 test or not tested (counterfactual group contains both participants who have a negative COVID-19 test result and participants who were not tested (n=426,875)).

Polypharmacy and COVID-19.

Compared to those taking no medications, in the fully adjusted model (Model 2) there was a clear dose relationship whereby the risk of a COVID-19 positive test rose steadily with polypharmacy level (Table 2): 4-6 medications (RR 1.41 (1.18-1.67) p<0.01); 7-9 medications (RR 1.86 (1.49-2.33) p<0.01); and  $\geq$ 10 medications (RR 2.42 (1.82-3.21) p<0.01).

Interactions between COVID-19 prognostic factors and multimorbidity

For all risk factors examined, there was a general trend of higher risk of a positive COVID-19 test with increasing LTCs and at-risk subgroups (Figure 1; Table 3). Further, for all prognostic factors, in participants with ≥2 LTCs there was a higher risk of a positive COVID-19 test for each risk factor subgroup when examining ethnicity, physical activity, BMI, systolic blood pressure, and eGFR. For some factors, having ≥2 LTCs was associated with an increased risk of COVID-19 infection only in the at-risk sub-group: males when examining sex; >65 years when examining age; and current/previous smoker when examining smoking status. When observing the effect of socioeconomic status, significantly higher risk of COVID-19 infection was apparent in the more deprived quintiles. There was no evidence of a multiplicative interaction between all risk factors modelled and number of LTCs. However, there appeared

to be an additive effect whereby the combination of multimorbidity and each prognostic factor was associated with greater risk of COVID-19 infection.

**Figure 1:** Relative risk of positive COVID-19 test by long-term condition count and prognostic factors (Poisson regression).

#### [Insert Fig1 here]

Figure 1 footnote - Prognostic factors: a) Sex, b) Age (years), c) Ethnicity, d) Townsend quintile (1 least deprived; 5 most deprived), e) Smoking status, f) Physical activity level (based on UK guidelines), g) Body-mass index (BMI; kg/m²), h) Systolic blood pressure (mmHg), and i) estimated glomerular filtration rate (eGFR; ml/min/1.73m²). Models were adjusted for sex, age, ethnicity, Townsend score, smoking status, alcohol intake frequency, physical activity, BMI, and assessment centre location.

Table 3 – Relative risk of positive COVID-19 test by LTC count and prognostic factors (Poisson regression)

Prognostic factor	LTC count	Prognostic factor subgroup	N	Relative risk (95% CI)	P value
	0	Female	80,212	1 (ref)	
		Male	68,965	1.08 (0.87-1.33)	0.51
Sex	1	Female	76,383	0.95 (0.77-1.18)	0.67
Sex	1	Male	63,965	1.39 (1.13-1.71)	***
	≥2	Female	77,492	1.24 (1.01-1.51)	0.04
	22	Male	59,588	1.88 (1.54-2.29)	***
	0	< 65	16,470	1 (ref)	
		≥ 65	132,707	0.66 (0.53-0.82)	***
Age at COVID-19 test	1	< 65	25,029	1.07 (0.87-1.31)	0.51
(years)	1	≥ 65	115,319	0.82 (0.68-1.00)	0.05
	≥2	< 65	36,865	0.99 (0.79-1.25)	0.96
		≥ 65	100,215	1.29 (1.09-1.53)	***
Faloninia.	0	White	138,677	1 (ref)	
		Other	9,492	1.84 (1.34-2.54)	***
	1	White	131,644	1.10 (0.94-1.29)	0.24
Ethnicity		Other	8,055	2.28 (1.67-3.11)	***
	≥2	White	129,033	1.47 (1.26-1.72)	***
		Other	7,408	2.81 (2.09-3.78)	***
		1	30,995	1 (ref)	
Townsend quintile		2	31,206	1.24 (0.84-1.82)	0.28
(1-least deprived; 5-most deprived)	0	3	30,394	1.19 (0.80-1.75)	0.39
		4	29,633	1.46 (1.01-2.12)	0.04
		5	26,956	1.96 (1.37-2.80)	***

•					
	1	1	28,723	1.47 (1.00-2.14)	0.05
		2	28,898	1.34 (0.92-1.97)	0.13
		3	28,605	1.39 (0.95-2.04)	0.09
		4	27,950	1.79 (1.25-2.46)	***
		5	26,005	1.79 (1.19-2.70)	***
		1	25,310	1.57 (1.07-2.30)	0.02
		2	26,585	1.75 (1.21-2.52)	***
	≥2	3	26,771	1.77 (1.23-2.55)	***
		4	27,764	2.22 (1.57-3.15)	***
		5	20,670	2.79 (2.00-3.90)	***
	0	never	88,737	1 (ref)	
	0	current/previous	59,500	1.26 (1.02-1.57)	0.03
	4	never	77,915	1.18 (0.96-1.44)	0.11
Smoking status	1	current/previous	61,781	1.33 (1.08-1.65)	0.01
		never	68,324	1.39 (1.14-1.70)	***
	≥2	current/previous	67,956	1.97 (1.62-2.38)	***
	0	≥ guidelines	80,715	1 (ref)	
	0	< guidelines	36,507	1.44 (1.09-1.91)	0.01
	1	≥ guidelines	74,324	1.32 (0.94-1.83)	0.11
Physical activity level		< guidelines	32,998	1.51 (1.13-2.00)	***
	≥2	≥ guidelines	68,226	1.87 (1.40-2.67)	***
		< guidelines	29,622	1.95 (1.43-2.67)	***
	0	<40	146,986	1 (ref)	
		≥40	1,094	1.30 (0.49-3.50)	0.60
BMI (kg/m²)	1	<40	137,865	1.14 (0.99-1.33)	0.08
		≥40	1,912	1.34 (0.63-2.85)	0.44
	≥2	<40	131,416	1.54 (1.33-1.78)	***
		≥40	4,865	2.66 (1.88-3.76)	***
	0	<140	97,526	1 (ref)	
		≥140	47,162	0.88 (0.69-1.11)	0.28
Systolic blood		<140	78,786	1.10 (0.91-1.32)	0.33
pressure (mm Hg)	1	≥140	57,921	1.04 (0.84-1.29)	0.73
,	≥2	<140	68,956	1.40 (1.16-1.69)	***
		≥140	63,979	1.46 (1.32-1.78)	***
	0	≥ 60	137,083	1 (ref)	
		< 60	1,270	0.74 (0.18-2.96)	0.67
eGFR	1	≥ 60	128,860	1.09 (0.93-1.28)	0.26
(ml/min/1.73m <sup>2</sup> )		< 60	2,108	2.14 (1.17-3.92)	0.01
	≥2	≥ 60	123,182	1.43 (1.22-1.67)	***
		< 60	4,981	2.13 (1.46-3.12)	***
			,	7	

Table 3 footnote - Models were adjusted for sex, age, ethnicity, Townsend score, smoking status, alcohol intake frequency, physical activity, BMI, and assessment centre location. LTC=long-term condition; BMI=body mass index; eGFR=estimated glomerular filtration rate;

guidelines = UK guidelines of 150 min/week moderate or 75 min/week vigorous physical

activity. \*\*\*p<0.01

Similar results overall were observed in the secondary analysis, where the above analyses

were repeated in those who were tested for COVID-19 versus those who were not

(Supplementary Material, Tables S1-S3).

**Discussion** 

Summary of key findings

This study showed that participants with multimorbidity (≥2 LTCs) had a 48% higher risk of a

positive COVID-19 test, those with cardiometabolic multimorbidity had a 77% higher risk,

and those with respiratory multimorbidity a 78% higher risk (albeit not statistically

significant, p=0.02), compared to those without that type of multimorbidity. Importantly,

those from non-white ethnicities with multimorbidity had nearly three times the risk of

having COVID-19 infection compared to those of white ethnicity, suggesting that those from

minority ethnic groups with multimorbidity are at particular risk. COVID-19 prognostic

factors appeared to have an additive effect by further increasing the risk of a positive

COVID-19 test in those with multimorbidity.

Comparison with previous literature

Previous literature has suggested that the presence of single LTCs such as hypertension,

diabetes, or COPD increase the risk of COVID-19.(33) In an English primary care research

cohort of 3,802 patients, confirmed COVID-19 infections were associated with male sex,

black ethnicity, deprivation, chronic kidney disease, and urban setting.(30) A preprint report

of linked primary care data on 17,425,445 adults in England, showed that older age, male

sex, deprivation, and black and Asian ethnicity were associated with higher risk of COVID-19

related in-hospital deaths.(11) However, our study is the first to show a higher risk of a

positive COVID-19 test in those with ≥2 LTCs and particularly in those with cardiometabolic

multimorbidity.

It has also been suggested that the presence of multimorbidity could further increase the

risk of adverse outcomes for people with COVID-19.(33) Guan et al, in a cohort of 1,590

hospital patients with confirmed COVID-19, found a higher risk of a composite COVID-19

outcome (intensive care admission, invasive ventilation, or death) in those with 1 (HR 1.79

(95%CI 1.16-2.77)) and 2 (HR 2.59 (95%CI 1.61-4.17) comorbidities.(9) However, while they

provided details of specific LTCs most likely to be present, especially in severe cases of

infection (hypertension, cardiovascular/cerebrovascular diseases, diabetes, hepatitis B

infections, COPD, chronic kidney diseases and malignancy), they did not describe which

patterns of multimorbidity were associated with the greatest risk. A report on 3,200

patients with COVID-19 from Italy showed that, of the 481 patients who died, 48.6% had 3

or more comorbidities. However, again, while it listed the specific LTCs associated with

increased risk, such as ischaemic heart disease and diabetes, it did not describe which

patterns of multimorbidity were associated with the highest risk.(13)

Strengths and limitations

As a large prospective cohort with rich demographic, lifestyle, health, and anthropometric

data linked to COVID-19 test results, UK Biobank provides a valuable opportunity to examine

the predictors for COVID-19.(34, 35) In particular, the rich data allowed examination of the

risk of a positive COVID-19 test in those with multimorbidity and the influence of a range of known sociodemographic, lifestyle and physiological risk factors for COVID-19. However, our study has a number of limitations. Firstly, the proportion of UK Biobank participants with COVID-19 test data is currently low (1.05%) which resulted in wide confidence intervals for groups with few participants. Secondly, the denominator for the test group included all those who had a negative test result as well as those who were not tested at all. At the time for which COVID-19 test data are available, the strategy in the UK had been to only test those in hospital (emergency department and inpatient) settings. This means the positive COVID-19 participants are likely to have had sufficiently severe clinical signs and symptoms to justify hospital assessment and those with COVID-19 but with mild symptoms are less likely to have been tested. Our results are therefore likely to reflect the associations with more severe COVID-19 disease. Thirdly, exposures and moderators examined here were assessed at baseline only and may have changed during follow up. However, LTC and medication count are likely to have remained the same or increased with time and therefore our effect size estimates may be conservative. Fourthly, UK Biobank participants are not representative of the general population and are acknowledged to be mostly white British, more affluent, and healthier than the general population. (36) Consequently, absolute values may not be generalisable, however, effect size estimates will be and strongly agree with more representative cohorts.(37)

*Implications* 

Our work has clinical and practical implications as more countries navigate lifting COVID-19 restrictions. It demonstrates that multimorbidity, particularly cardiometabolic multimorbidity and polypharmacy, are strongly associated with COVID-19 infection and

suggests that those who have multimorbidity coupled with additional risk factors, such as

non-white ethnicity, are at increased risk. Such individuals should be particularly stringent in

adhering to preventive measures, such as physical distancing and hand hygiene. Our

findings also have implications for clinicians, occupational health and employers when

considering work-place environments, appropriate advice for patients, and adaptations that

might be required to protect such staff.

Future research is needed to corroborate these findings in other countries and in people

from different ethnic backgrounds. We know that patterns of multimorbidity differ across

ethnic groups and have different associations with mortality, so this merits further

investigation.(38) We also need to explore the implications of different patterns of

multimorbidity on COVID-19 related health care outcomes in the short and long term.

**Conclusion** 

This study suggests that multimorbidity, cardiometabolic disease, and polypharmacy are

associated with COVID-19. Those with multimorbidity who were also of non-white ethnicity,

from the most socioeconomically deprived backgrounds, those who were severely obese, or

who had reduced renal function, had more than twice the risk of COVID-19 infection.

More work is required to develop risk stratification for COVID-19 in people with different

patterns of multimorbidity in order to better define those individuals who would benefit

21

from enhanced preventive measures in public, work, and residential spaces.

# Acknowledgements

The authors would like to thank the participants of UK Biobank and the UK Biobank for access to this data.

## Conflicts of interest

JPP is a member of the Scientific Advisory Committee of UK Biobank. All other authors have no potential, perceived, or real conflicts of interest.

## References

- 1. World Health Organisation: Coronavirus disease 2019 (COVID-19) Situation Report 22. <a href="https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200211-sitrep-22-ncov.pdf?sfvrsn=fb6d49b1">https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200211-sitrep-22-ncov.pdf?sfvrsn=fb6d49b1</a> 2; 2020.
- 2. World Health Organisation Director-General's opening remarks at the media briefing on COVID-19 11 March 2020. 2020.
- 3. Coronaviridae Study Group of the International Committee on Taxonomy of V. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536-44.
- 4. Zhu J, Ji P, Pang J, Zhong Z, Li H, He C, et al. Clinical characteristics of 3,062 COVID-19 patients: a meta-analysis. Journal of Medical Virology. 2020.
- 5. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. 2020.
- 6. GLOBAL\_HEALTH5050. COVID-19 sex-disaggregated data tracker 2020 [Available from: https://globalhealth5050.org/covid19/
- 7. ONS. Coronavirus (COVID-19) related deaths by ethnic group, England and Wales: 2 March 2020 to 10 April 2020 (UK Office for National Statistics). 2020.
- 8. Sattar N, McInnes IB, McMurray JJV. Obesity a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms. Circulation. 2020.
- 9. Guan W-J, Liang W-H, Zhao Y, Liang H-R, Chen Z-S, Li Y-M, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. European Respiratory Journal. 2020;55(5):2000547.
- 10. Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia A systematic review, meta-analysis, and meta-regression. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020;14(4):395-403.
- 11. Collaborative TO. MedRxiv preprint OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. 2020.

- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
- 13. ISS. Istituto Superiore di Sanità: Characteristics of COVID-19 patients dying in Italy Report based on available data on March 26th, 2020. . 2020.
- 14. Centers for Disease Control and Prevention: Coronavirus Disease 2019 (COVID-19): People Who Are at Higher Risk for Severe Illness. 2020.
- 15. UK Cabinet Office: Staying at home and away from others (social distancing) 2020.
- 16. PHE. Guidance on shielding and protecting people who are clinically extremely vulnerable from COVID-19. 2020.
- 17. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985.
- 18. Tran J, Norton R, Conrad N, Rahimian F, Canoy D, Nazarzadeh M, et al. Patterns and temporal trends of comorbidity among adult patients with incident cardiovascular disease in the UK between 2000 and 2014: A population-based cohort study. PLoS Med. 2018;15(3):e1002513.
- 19. Arokiasamy P, Uttamacharya U, Jain K, Biritwum RB, Yawson AE, Wu F, et al. The impact of multimorbidity on adult physical and mental health in low- and middle-income countries: what does the study on global ageing and adult health (SAGE) reveal? BMC Med. 2015;13:178.
- 20. Garin N, Koyanagi A, Chatterji S, Tyrovolas S, Olaya B, Leonardi M, et al. Global Multimorbidity Patterns: A Cross-Sectional, Population-Based, Multi-Country Study. J Gerontol A Biol Sci Med Sci. 2016;71(2):205-14.
- 21. Jani BD, Hanlon P, Nicholl BI, McQueenie R, Gallacher KI, Lee D, et al. Relationship between multimorbidity, demographic factors and mortality: findings from the UK Biobank cohort. BMC Med. 2019;17(1):74.
- 22. Corsonello A, Pedone C, Corica F, Incalzi RA. Polypharmacy in elderly patients at discharge from the acute care hospital. Ther Clin Risk Manag. 2007;3(1):197-203.
- 23. Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995-2010. BMC Med. 2015;13:74.
- 24. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12(3):e1001779.
- 25. UKBiobank. COVID-19 test results data 2020 [Available from: http://biobank.ndph.ox.ac.uk/ukb/exinfo.cgi?src=COVID19 tests.
- 26. Townsend P, Philimore, P., Beattie, A. . Health and deprivation: inequality and the North.: Croom Helm; 1987.
- 27. IPAQ. IPAQ scoring protocol 2005 [Available from: <a href="https://sites.google.com/site/theipaq/scoring-protocol">https://sites.google.com/site/theipaq/scoring-protocol</a>.
- 28. Elliott P, Peakman TC. The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. International Journal of Epidemiology. 2008;37(2):234-44.
- 29. UK Chief Medical Officers' Physical Activity Guidelines 2019.
- 30. De Lusignan S, Dorward J, Correa A, Jones N, Akinyemi O, Amirthalingam G, et al. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General

Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. The Lancet Infectious Diseases. 2020.

- 31. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-12.
- 32. Zou GY, Donner A. Extension of the modified Poisson regression model to prospective studies with correlated binary data. Stat Methods Med Res. 2013;22(6):661-70.
- 33. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020.
- 34. Hastie CE, Mackay DF, Ho F, Celis-Morales CA, Katikireddi SV, Niedzwiedz CL, et al. Vitamin D concentrations and COVID-19 infection in UK Biobank. Diabetes Metab Syndr. 2020;14(4):561-5.
- 35. Niedzwiedz CL, O'Donnell CA, Jani BD, Demou E, Ho FK, Celis-Morales C, et al. Ethnic and socioeconomic differences in SARS-CoV-2 infection: prospective cohort study using UK Biobank. medRxiv. 2020:2020.04.22.20075663.
- 36. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. Am J Epidemiol. 2017;186(9):1026-34.
- 37. Batty GD, Gale CR, Kivimäki M, Deary IJ, Bell S. Comparison of risk factor associations in UK Biobank against representative, general population based studies with conventional response rates: prospective cohort study and individual participant meta-analysis. BMJ. 2020:m131.
- 38. Chiang JI, Hanlon P, Li TC, Jani BD, Manski-Nankervis JA, Furler J, et al. Multimorbidity, mortality, and HbA1c in type 2 diabetes: A cohort study with UK and Taiwanese cohorts. PLoS Med. 2020;17(5):e1003094.

